Germline Genetic Testing After Cancer Diagnosis
JAMA · 03.07.2023 · 330 (1) · 43
DOI: 10.1001/jama.2023.9526 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 03.07.2023. Verfasst von Allison W Kurian und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Breast Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 172-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention.
Objective
To describe the prevalence of germline genetic testing among patients diagnosed with cancer in California and Georgia between 2013 and 2019. Design, Setting, and Participants Observational study including patients aged 20 years or older who had been diagnosed with any type of cancer between January 1, 2013, and March 31, 2019, that was reported to statewide Surveillance, Epidemiology, and End Results registries in California and Georgia. These patients were linked to genetic testing results from 4 laboratories that performed most germline testing for California and Georgia. Main Outcomes and Measures The primary outcome was germline genetic testing within 2 years of a cancer diagnosis. Testing trends were analyzed with logistic regression modeling. The results of sequencing each gene, including variants associated with increased cancer risk (pathogenic results) and variants whose cancer risk association was unknown (uncertain results), were evaluated. The genes were categorized according to their primary cancer association, including breast or ovarian, gastrointestinal, and other, and whether practice guidelines recommended germline testing.
Results
Among 1 369 602 patients diagnosed with cancer between 2013 and 2019 in California and Georgia, 93 052 (6.8%) underwent germline testing through March 31, 2021. The proportion of patients tested varied by cancer type: male breast (50%), ovarian (38.6%), female breast (26%), multiple (7.5%), endometrial (6.4%), pancreatic (5.6%), colorectal (5.6%), prostate (1.1%), and lung (0.3%). In a logistic regression model, compared with the 31% (95% CI, 30%-31%) of non-Hispanic White patients with male breast cancer, female breast cancer, or ovarian cancer who underwent testing, patients of other races and ethnicities underwent testing less often: 22% (95% CI, 21%-22%) of Asian patients, 25% (95% CI, 24%-25%) of Black patients, and 23% (95% CI, 23%-23%) of Hispanic patients ( P < .001 using the χ 2 test). Of all pathogenic results, 67.5% to 94.9% of variants were identified in genes for which practice guidelines recommend testing and 68.3% to 83.8% of variants were identified in genes associated with the diagnosed cancer type. Conclusions and Relevance Among patients diagnosed with cancer in California and Georgia between 2013 and 2019, only 6.8% underwent germline genetic testing. Compared with non-Hispanic White patients, rates of testing were lower among Asian, Black, and Hispanic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, School of Medicine, Stanford University, Stanford, California.
- Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California.
- Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.
- Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles.
Förderung
- NCI NIH HHS
Zitieren
APA
Kurian, A. W., Abrahamse, P., Furgal, A., Ward, K. C., Hamilton, A. S., Hodan, R., Tocco, R., Liu, L., Berek, J. S., Hoang, L., Yussuf, A., Susswein, L., Esplin, E. D., Slavin, T. P., Gomez, S. L., Hofer, T. P., & Katz, S. J. (2023). Germline Genetic Testing After Cancer Diagnosis. JAMA, 330(1), 43. https://doi.org/10.1001/jama.2023.9526
Vancouver
Kurian AW, Abrahamse P, Furgal A, Ward KC, Hamilton AS, Hodan R, et al. Germline Genetic Testing After Cancer Diagnosis. JAMA. 2023;330(1):43. doi:10.1001/jama.2023.9526
BibTeX
@article{Kurian2023,
author = {Kurian, Allison W and Abrahamse, Paul and Furgal, Allison and Ward, Kevin C and Hamilton, Ann S and Hodan, Rachel and Tocco, Rachel and Liu, Lihua and Berek, Jonathan S and Hoang, Lily and Yussuf, Amal and Susswein, Lisa and Esplin, Edward D and Slavin, Thomas P and Gomez, Scarlett L and Hofer, Timothy P and Katz, Steven J},
title = {Germline Genetic Testing After Cancer Diagnosis},
journal = {JAMA},
year = {2023},
volume = {330},
number = {1},
pages = {43},
doi = {10.1001/jama.2023.9526}
}
EUVIMED